Limited Anti-Inflammatory Role for Interleukin-1 Receptor Like 1 (ST2) in the Host Response to Murine Postinfluenza Pneumococcal Pneumonia

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Blok, Dana C ^a   van der Sluijs, Koenraad F ^a   Florquin, Sandrine ^a   de Boer, Onno J ^a   van 't Veer, Cornelis ^a   de Vos, Alex F ^a   van der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL LOAD; BODY WEIGHT; CELL ACTIVITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME BLOOD LEVEL; HOST RESISTANCE; IMMUNE RESPONSE; INFECTION COMPLICATION; INFLUENZA A; INFLUENZA VIRUS A; MOUSE; NEUTROPHIL; NONHUMAN; PNEUMONIA; PRIMARY INFECTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SECONDARY INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TISSUE LEVEL; VIRAL CLEARANCE;

ANIMALS; HISTOLOGICAL TECHNIQUES; INFLAMMATION; INFLUENZA A VIRUS; LUNG; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; RECEPTORS, INTERLEUKIN; STATISTICS, NONPARAMETRIC;

EID: 84874632292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058191     Document Type: Article

References (61)

1. Clark NM, Lynch JP 3rd (2011) Influenza: epidemiology, clinical features, therapy, and prevention. Semin Respir Crit Care Med 32: 373-392.
2. Thompson WW, Comanor L, Shay DK, (2006) Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194Suppl 2: S82-91.
3. Morens DM, Taubenberger JK, Fauci AS, (2008) Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198: 962-970.
4. McCullers JA, (2006) Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19: 571-582.
5. Grabowska K, Hogberg L, Penttinen P, Svensson A, Ekdahl K, (2006) Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis 6: 58.
6. Irizarry-Acosta M, Puius YA (2010) Post-influenza pneumonia: everything old is new again. Med Health R I 93: 204-207, 211.
7. Klugman KP, Chien YW, Madhi SA, (2009) Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 27Suppl 3: C9-C14.
8. van der Sluijs KF, van der Poll T, Lutter R, Juffermans NP, Schultz MJ, (2010) Bench-to-bedside review: bacterial pneumonia with influenza- pathogenesis and clinical implications. Crit Care 14: 219.
9. Ballinger MN, Standiford TJ, (2010) Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res 30: 643-652.
10. Alicino C, Iudici R, Alberti M, Durando P, (2011) The dangerous synergism between influenza and Streptococcus pneumoniae and innovative perspectives of vaccine prevention. J Prev Med Hyg 52: 102-106.
11. Beutler BA, (2009) TLRs and innate immunity. Blood 113: 1399-1407.
12. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C, (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531.
13. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. (2004) Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 101: 5598-5603.
14. Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, et al. (2007) Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 178: 3368-3372.
15. Seo SU, Kwon HJ, Song JH, Byun YH, Seong BL, et al. (2010) MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol 84: 12713-12722.
16. Knapp S, Wieland CW, van 't Veer C, Takeuchi O, Akira S, et al. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J Immunol 172: 3132-3138.
17. Mogensen TH, Paludan SR, Kilian M, Ostergaard L, (2006) Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J Leukoc Biol 80: 267-277.
18. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100: 1966-1971.
19. Srivastava A, Henneke P, Visintin A, Morse SC, Martin V, et al. (2005) The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 73: 6479-6487.
20. Lee KS, Scanga CA, Bachelder EM, Chen Q, Snapper CM, (2007) TLR2 synergizes with both TLR4 and TLR9 for induction of the MyD88-dependent splenic cytokine and chemokine response to Streptococcus pneumoniae. Cell Immunol 245: 103-110.
21. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, et al. (2007) Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 9: 633-644.
22. Albiger B, Sandgren A, Katsuragi H, Meyer-Hoffert U, Beiter K, et al. (2005) Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol 7: 1603-1615.
23. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, et al. (2008) Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 205: 323-329.
24. Giamarellos-Bourboulis EJ, Raftogiannis M, Antonopoulou A, Baziaka F, Koutoukas P, et al. (2009) Effect of the novel influenza A (H1N1) virus in the human immune system. PLoS One 4: e8393.
25. Karlstrom A, Heston SM, Boyd KL, Tuomanen EI, McCullers JA, (2011) Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 204: 1358-1366.
26. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, et al. (2004) ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 5: 373-379.
27. Liew FY, Xu D, Brint EK, O'Neill LA, (2005) Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 5: 446-458.
28. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, et al. (2004) IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172: 7603-7609.
29. Dessing MC, van der Sluijs KF, Florquin S, Akira S, van der Poll T, (2007) Toll-like receptor 2 does not contribute to host response during postinfluenza pneumococcal pneumonia. Am J Respir Cell Mol Biol 36: 609-614.
30. van der Sluijs KF, Nijhuis M, Levels JH, Florquin S, Mellor AL, et al. (2006) Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 193: 214-222.
31. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Florquin S, et al. (2006) Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 290: L194-199.
32. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN, (2000) T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 191: 1069-1076.
33. van der Sluijs KF, van Elden L, Nijhuis M, Schuurman R, Florquin S, et al. (2003) Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus. Immunol Lett 89: 201-206.
34. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, et al. (2002) Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 168: 3507-3511.
35. van der Windt GJ, Blok DC, Hoogerwerf JJ, Lammers AJ, de Vos AF, et al. (2012) Interleukin 1 receptor-associated kinase m impairs host defense during pneumococcal pneumonia. J Infect Dis 205: 1849-1857.
36. Kager LM, Wiersinga WJ, Roelofs JJ, Meijers JC, Levi M, et al. (2011) Plasminogen activator inhibitor type I contributes to protective immunity during experimental Gram-negative sepsis (melioidosis). J Thromb Haemost 9: 2020-2028.
37. Kozak W, Poli V, Soszynski D, Conn CA, Leon LR, et al. (1997) Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 272: R621-630.
38. Dessing MC, van der Sluijs KF, Spek CA, van der Poll T, (2009) Gene expression profiles in murine influenza pneumonia. J Innate Immun 1: 366-375.
39. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, et al. (2011) Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 12: 1055-1062.
40. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, et al. (2011) Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 12: 1045-1054.
41. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, et al. (2012) IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 188: 1503-1513.
42. LeVine AM, Koeningsknecht V, Stark JM, (2001) Decreased pulmonary clearance of S. pneumoniae following influenza A infection in mice. J Virol Methods 94: 173-186.
43. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA, (2007) Induction of pro- and anti-inflammatory molecules in a mouse model of pneumococcal pneumonia after influenza. Comp Med 57: 82-89.
44. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, et al. (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52: 89-99.
45. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
46. van der Poll T, Opal SM, (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 374: 1543-1556.
47. Paterson GK, Orihuela CJ, (2010) Pneumococci: immunology of the innate host response. Respirology 15: 1057-1063.
48. Sun K, Metzger DW, (2008) Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 14: 558-564.
49. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK, (2008) IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 180: 2443-2449.
50. Jiang HR, Milovanovic M, Allan D, Niedbala W, Besnard AG, et al. (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 42: 1804-1814.
51. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, et al. (2009) Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27: 3481-3483.
52. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, et al. (2011) Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 8: 97.
53. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE, (2012) Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 7: e30596.
54. Hotchkiss RS, Karl IE, (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150.
55. Adib-Conquy M, Cavaillon JM, (2009) Compensatory anti-inflammatory response syndrome. Thromb Haemost 101: 36-47.
56. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, et al. (1999) IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 162: 392-399.
57. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, et al. (2006) Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116: 2532-2542.
58. Hoogerwerf JJ, Leendertse M, Wieland CW, de Vos AF, de Boer JD, et al. (2011) Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am J Respir Crit Care Med 183: 932-940.
59. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, et al. (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202.
60. Seki M, Kohno S, Newstead MW, Zeng X, Bhan U, et al. (2010) Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J Immunol 184: 1410-1418.
61. Hoogerwerf JJ, Van Der Windt GJ, Blok DC, Hoogendijk AJ, De Vos AF, et al. (2012) Interleukin-1 Receptor-Associated Kinase M-Deficient Mice Demonstrate an Improved Host Defense during Gram-negative Pneumonia. Mol Med 18: 1067-1075.